Myriad Genetics (MYGN): CEO sold ~$344K
Paul J Diaz, CEO at Myriad Genetics, sold ~$344K of Myriad Genetics shares.
- ~$344K
- Approx. value · 15K sh @ $22.93
- 962K
- Holds after · shares reported
- Traded
- Oct 11, 2024
- Filed
- Oct 11, 2024
What stands out in this filing
- The sale was 1.5% of the shares this insider held before it; the filing reports 962,378 shares afterwards.
- 15,000 shares at an average of $22.93 each, as reported on the form.
- Footnote references a pre-arranged trading plan (Rule 10b5-1).
Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Myriad Genetics
For Myriad Genetics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MYGN page.
How this filing works
Explore the data
Common questions
Which Myriad Genetics (MYGN) insider traded, and how much?
Paul J Diaz, CEO at Myriad Genetics, sold ~$344K of Myriad Genetics shares. 15K shares at $22.93.
When did it happen, and when was it made public?
Traded: Oct 11, 2024. Filed: Oct 11, 2024.
What stands out in this filing?
The sale was 1.5% of the shares this insider held before it; the filing reports 962,378 shares afterwards. 15,000 shares at an average of $22.93 each, as reported on the form. Footnote references a pre-arranged trading plan (Rule 10b5-1).
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Myriad Genetics recently?
For Myriad Genetics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days. They are listed on the MYGN page.
Does this mean MYGN stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Myriad Genetics
- SEC Schedule 13GNov 16, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRMay 15, 2026
- SEC Form 13F-HRAug 14, 2025
- SEC Form 13F-HRAug 14, 2025
- SEC Form 13F-HRMay 15, 2025
Everything OQRO holds on this company is on its MYGN page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
